Sponsored Insight by Janssen Research & Development, LLC.
Precision medicine for major depressive disorder has the potential to address critical, unmet needs
Nearly 70% of people with major depressive disorder (MDD) treated with antidepressant drugs from the selective serotonin reuptake inhibitor class experience residual symptoms like anxiety, impaired cognition, insomnia, fatigue, and anhedonia. Fortunately, neuroscience is entering a new era of precision medicine based on scientific and digital advances. Scientists are evaluating how to recognize illness subtypes and predict which people with MDD will respond to a particular treatment. Read the article here.
California moves to revoke CVS mail-order license; realigning the moral compass for sickle cell care
Reviewed by Knowledge World
on
December 21, 2022
Rating: 5
Post Comment
No comments